FDA releases silicone breast implants from tracking rules
This article was originally published in Clinica
The US FDA has exempted a number of manufacturers from its mandatory tracking requirements after concluding that their products are not risky enough to warrant the added regulatory burden. The exemption includes companies that make silicone gel implants and saline breast implants.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.